Navigation Links
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights


Safe Harbor

This press release and the conference call to follow may contain forward- looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product


-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertai

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:10/8/2015)... 2015 ® ) in ... The NOCT study also assessed the compliance, safety, ... ® ) in adult patients undergoing screening, ... assessed the compliance, safety, patient acceptability and tolerability ... positive top line results for its phase III ...
(Date:10/8/2015)... Calif. , Oct. 8, 2015  Ardelyx, ... company focused on gastrointestinal and cardio-renal diseases, today ... product candidate, tenapanor, will be presented at the ... presented findings will include measures of sustained response ... double blind, placebo-controlled, randomized Phase 2 trial. The ...
(Date:10/8/2015)... plc (NYSE: AGN ), a leading global pharmaceutical ... Day on November 4, from 11:00 a.m. to 4:00 ... The company will also host its third-quarter 2015 conference ... a.m. PT). ... - Irvine, ...
Breaking Medicine Technology:
... Dec. 1, 2011 Mylan Inc. (Nasdaq: MYL ) ... Besylate and Atorvastatin Calcium Tablets, 2.5 mg/10 mg, 2.5 mg/20 mg, ... mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 ... Caduet ® Tablets, which are used in the treatment of ...
... 2011  Henry Schein, Inc., (NASDAQ: HSIC ), ... to office-based practitioners, announced today that Stanley Bergman, Chairman ... Paladino, the Company,s Executive Vice President and Chief Financial ... Program on December 6.  The conference is being held ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... BrightStar Care® ... by Cabarrus County Active Living and Parks for its outstanding commitment to volunteering ... dedication to consistently going above and beyond the call of duty, seniors on ...
(Date:10/9/2015)... Phoenix, AZ (PRWEB) , ... October 09, 2015 , ... ... Dignity Health Arizona General Hospital Emergency Room – Chandler–McQueen opening later this month. ... which opened earlier this year in the West Valley. , “Dr. Morro is ...
(Date:10/9/2015)... MA (PRWEB) , ... October 09, 2015 , ... When ... a ventilation solution for their latest project in West Hollywood, CA, they turned to ... the perfect fit for this pristine, Craftsman-style bungalow, and because of our successful past ...
(Date:10/9/2015)... ... 2015 , ... Bag Tags Inc. will provide custom bag ... at the annual IRONMAN World Championship in Kailua-Kona, Hawaii, this Saturday, October ... taken place in Hawaii every year since 1978. , As part of its ...
(Date:10/8/2015)... , ... October 09, 2015 , ... ... its five year anniversary this November. The support post-concussion group was started by ... Athletic Trainers’ Society (PATS) member. The group was started in November 2010 ...
Breaking Medicine News(10 mins):
... Simulator, from Electronic Sports, leads the next generation of exergaming fitness ... fun. , ... Salt Lake City, UT (PRWEB) December ... Dogfight, a full featured flight simulator interfaced with a high-end exercise ...
... PORTAGE, Ind., Dec. 16 MonoSol Rx, the ... company specializing in dissolving thin film pharmaceutical products, ... an agreement for thin film pharmaceutical products with ... a multinational pharmaceutical group focused on developing, manufacturing ...
... second Indiana Planned Parenthood clinic shows an emerging pattern of ... report the statutory rape of young girls. The new footage ... Project," a series of investigations documenting how secret abortions keep ... , In the video, shot undercover ...
... England and SAN FRANCISCO, Dec. 16 Enigma Diagnostics ... today that it has signed a term sheet for ... (RMS). , , The ... or licensed by RMS and its affiliates to practice ...
... BOTHELL, Wash., Dec. 16 SCOLR Pharma, Inc. (NYSE Alternext: DDD) ... Officer of the Company and as a member of its Board ... , Michael N. Taglich, Chairman of the Board of ... SCOLR,s entire organization, I would like to thank Dan for his ...
... Healthways executive brings 14-plus years of health industry expertise ... MINNEAPOLIS, Dec. 16 HealthFitness (NYSE Alternext ... as senior vice president of business and corporate development. ... services for on-site and dispersed employee populations. , ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: